瑞舒伐他汀对急性冠脉综合征血脂和高敏C反应蛋白的影响

目的:观察不同剂量瑞舒伐他汀治疗急性冠脉综合征患者血脂和高敏C反应蛋白的疗效及安全性。方法:82例急性冠脉综合征患者随机分为A组(瑞舒伐他汀20mg/d,n=41)和B组(瑞舒伐他汀10mg/d,n=41);观察4周后两组血脂、hs-CRP水平和不良反应发生率等指标变化。结果:4周后A组、B组的LDL-C水平较治疗前均有显著下降,分别为(2.67±0.94 vs.2.13±0.64;P=0.005)、(2.68±0.77 vs.2.37±0.58;P=0.044),但两组的LDL-C达标率差异有统计学意义(70.1%vs.43.9%,P=0.014),治疗后hs-CRP水平小于10mg/L的比例两组差异有统计学意义(85.4%vs.58.5%,P=0.007),试验中两组均未发现与药物相关的严重不良反应事件。结论:瑞舒伐他汀20mg/d能更显著降低急性冠脉综合征患者血脂与高敏C反应蛋白水平,且具有良好的耐受性和安全性。

Effects of high dose rosuvastatin on plasma lipid level and hypersensitive C reaction protein(hs-CRP) in patients with acute coronary syndrome

Objective: To observe the influcence of rosuvastatin on plasma lipid level and hypersensitive C-reaction protein(hs-CRP) in patients with acute coronary syndrome and and its safety.Methods:A total of 82 patients with ACS were randomly divided into group A and group B.Group A were treated with rosuvastatin 20 mg/d(high dose) and group B treated with rosuvastatin 10 mg/d(routine dose),The lipid and hs-CRP level and adverse events were compared after 4 weeks.Results:After 4 weeks of treatment,LDL-C in both group A(2.67±0.94 vs 2.13±0.64;P=0.005) and group B(2.68±0.77 vs 2.37±0.58;P=0.044) decreased significantly,but more patients in group A resorted target LDL-C level than that in group B(70.1% vs 43.9%;P=0.014).Besides,the rate of patients showing hs-CRP less than 10 mg/L were significant different between the two groups(85.4% vs 58.5%;P=0.007).No drug-related serious adverse events occurred during the study.Conclusion: Rosuvastatin at the dosage of 20 mg/day can significantly reduce LDL-C and hs-CRP level in patients with acute coronary syndrome showing good tolerance and safety.